Shopping Cart 0
Cart Subtotal
AED 0

Global Biosimilars Market 2021-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Region: Trend Forecast and Growth Opportunity

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 11744

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 18350

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 24956

Details

Global biosimilars market will reach USD 113.25 billion by 2030, growing by 25.7% annually over 2020-2030 driven by the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent expirations of many blockbuster drugs, and better healthcare provisions.

Highlighted with 89 tables and 90 figures, this 180-page report Global Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Region: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire global biosimilars market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).

In-depth qualitative analyses include identification and investigation of the following aspects:

Market Structure

Growth Drivers

Restraints and Challenges

Emerging Product Trends & Market Opportunities

Porter's Fiver Forces

The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global biosimilars market in every aspect of the classification from perspectives of Product Type, Indication, Manufacturing, End User, and Region.

 

Based on Product Type, the global market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Recombinant Non-glycosylated Biosimilars

o Insulin

o Recombinant Human Growth Hormone (rHGH)

o Granulocyte Colony Stimulating Factor

o Interferon

Recombinant Glycosylated Biosimilars

o Monoclonal Antibodies (mAb)

o Erythropoietin (EPO)

o Follicle Stimulating Hormone

Recombinant Peptides and Others

o Tumor Necrosis Factor (TNF)-Inhibitor

o Parathyroid Hormone

o Enzymes, Immunomodulators, GnRH Analogs and Others

 

Based on Indication, the global market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Cancer

Autoimmune Disease

Blood Disorder

Diabetes

Growth Hormone Deficiency

Infectious Diseases

Other Indications

 

Based on Manufacturing, the global market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Contract Manufacturing

Inhouse Manufacturing

 

Based on End User, the global market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Hospitals and Clinics

Research Institutes

Other End Users

 

Geographically, the following regions together with the listed national/local markets are fully investigated:

North America (U.S., Canada, and Mexico)

Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)

APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)

South America (Brazil, Chile, Argentina, Rest of South America)

MEA (Turkey, Iran, South Africa)

For each aforementioned region and country, detailed analysis and data for annual revenue (USD mn) are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Product Type, Indication, and End User over the forecast years are also included.

 

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Key Players (this may not be a complete list and extra companies can be added upon request):

AMEGA Biotech S.A.

Apotex Inc.

Biocon Ltd

Biogen Inc.

Boehringer Ingelheim

Celltrion, Inc.

Dr. Reddy's Laboratories Ltd.

Eli Lilly and Company

Intas Pharmaceuticals Ltd.

LG Chem, Ltd.

Merck and Co. Inc.

Mylan N.V.

Pfizer Inc.

Samsung Biologics Co., Ltd.

Sandoz International GmbH

STADA Arzneimittel AG

Teva Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

READ MORE

Table Of Content

Scope

1 Introduction 9

1.1 Industry Definition and Research Scope 9

1.1.1 Industry Definition 9

1.1.2 Research Scope 10

1.2 Research Methodology 13

1.2.1 Overview of Market Research Methodology 13

1.2.2 Market Assumption 14

1.2.3 Secondary Data 14

1.2.4 Primary Data 14

1.2.5 Data Filtration and Model Design 15

1.2.6 Market Size/Share Estimation 16

1.2.7 Research Limitations 17

1.3 Executive Summary 18

2 Market Overview and Dynamics 20

2.1 Market Size and Forecast 20

2.1.1 Impact of COVID-19 on World Economy 23

2.1.2 Impact of COVID-19 on the Market 26

2.2 Major Growth Drivers 28

2.3 Market Restraints and Challenges 33

2.4 Emerging Opportunities and Market Trends 36

2.5 Porter's Fiver Forces Analysis 40

3 Segmentation of Global Market by Product Type 44

3.1 Market Overview by Product Type 44

3.2 Recombinant Non-glycosylated Biosimilars 46

3.2.1 Insulin 48

3.2.2 Recombinant Human Growth Hormone (rHGH) 49

3.2.3 Granulocyte Colony Stimulating Factor 50

3.2.4 Interferon 51

3.3 Recombinant Glycosylated Biosimilars 52

3.3.1 Monoclonal Antibodies (mAb) 53

3.3.2 Erythropoietin (EPO) 54

3.3.3 Follicle Stimulating Hormone 55

3.4 Recombinant Peptides and Others 56

3.4.1 Tumor Necrosis Factor (TNF)-Inhibitor 57

3.4.2 Parathyroid Hormone 58

3.4.3 Enzymes, Immunomodulators, GnRH Analogs and Others 59

4 Segmentation of Global Market by Indication 60

4.1 Market Overview by Indication 60

4.2 Cancer 62

4.3 Autoimmune Disease 63

4.4 Blood Disorder 64

4.5 Diabetes 65

4.6 Growth Hormone Deficiency 66

4.7 Infectious Diseases 67

4.8 Other Indications 68

5 Segmentation of Global Market by Manufacturing 69

5.1 Market Overview by Manufacturing 69

5.2 Contract Manufacturing 71

5.3 Inhouse Manufacturing 72

6 Segmentation of Global Market by End User 73

6.1 Market Overview by End User 73

6.2 Hospitals and Clinics 75

6.3 Research Institutes 76

6.4 Other End Users 77

7 Segmentation of Global Market by Region 78

7.1 Geographic Market Overview 2019-2030 78

7.2 North America Market 2019-2030 by Country 82

7.2.1 Overview of North America Market 82

7.2.2 U.S. 86

7.2.3 Canada 96

7.2.4 Mexico 98

7.3 European Market 2019-2030 by Country 100

7.3.1 Overview of European Market 100

7.3.2 Germany 106

7.3.3 U.K. 108

7.3.4 France 110

7.3.5 Spain 112

7.3.6 Italy 114

7.3.7 Russia 116

7.3.8 Rest of European Market 118

7.4 Asia-Pacific Market 2019-2030 by Country 120

7.4.1 Overview of Asia-Pacific Market 120

7.4.2 Japan 124

7.4.3 China 127

7.4.4 Australia 129

7.4.5 India 131

7.4.6 South Korea 133

7.4.7 Rest of APAC Region 135

7.5 South America Market 2019-2030 by Country 137

7.5.1 Argentina 140

7.5.2 Brazil 142

7.5.3 Chile 144

7.5.4 Rest of South America Market 146

7.6 MEA Market 2019-2030 by Country 147

7.6.1 Turkey 150

7.6.2 Iran 152

7.6.3 South Africa 154

7.6.4 Other National Markets 156

8 Competitive Landscape 157

8.1 Overview of Key Vendors 157

8.2 New Product Launch, Partnership, Investment, and M&A 161

8.3 Company Profiles 162

AMEGA Biotech S.A. 162

Apotex Inc. 164

Biocon Ltd 165

Biogen Inc. 166

Boehringer Ingelheim 167

Celltrion, Inc. 168

Dr. Reddy's Laboratories Ltd. 169

Eli Lilly and Company 170

Intas Pharmaceuticals Ltd. 171

LG Chem, Ltd. 172

Merck and Co. Inc. 173

Mylan N.V. 174

Pfizer Inc. 175

Samsung Biologics Co., Ltd. 176

Sandoz International GmbH 177

STADA Arzneimittel AG 178

Teva Pharmaceutical Industries Ltd. 179

RELATED REPORTS 180


List Of Figure

List of Figures:

 

Figure 1. Research Method Flow Chart 13

Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 16

Figure 3. Global Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 18

Figure 4. Global Biosimilars Market, 2019-2030, USD mn 20

Figure 5. EMA and FDA Biosimilar Approvals, 2015 - 2019 21

Figure 6. EMA-approved Biosimilars Distribution by Reference Product and Therapeutic Area 21

Figure 7. FDA-approved Biosimilars Distribution by Reference Product and Therapeutic Area 22

Figure 8. Impact of COVID-19 on Business 26

Figure 9. Primary Drivers and Impact Factors of Global Biosimilars Market 28

Figure 10. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 31

Figure 11. World Population 65 and Over, % of Total Population, 1950-2060 31

Figure 12. Primary Restraints and Impact Factors of Global Biosimilars Market 33

Figure 13. Investment Opportunity Analysis 37

Figure 14. Porter's Fiver Forces Analysis of Global Biosimilars Market 40

Figure 15. Breakdown of Global Biosimilars Market by Product Type, 2019-2030, % of Revenue 45

Figure 16. Global Addressable Market Cap in 2021-2030 by Product Type, Value (USD mn) and Share (%) 45

Figure 17. Global Biosimilars Market by Product Type: Recombinant Non-glycosylated Biosimilars, 2019-2030, USD mn 46

Figure 18. Global Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Insulin, 2019-2030, USD mn 48

Figure 19. Global Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Recombinant Human Growth Hormone (rHGH), 2019-2030, USD mn 49

Figure 20. Global Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Granulocyte Colony Stimulating Factor, 2019-2030, USD mn 50

Figure 21. Global Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Interferon, 2019-2030, USD mn 51

Figure 22. Global Biosimilars Market by Product Type: Recombinant Glycosylated Biosimilars, 2019-2030, USD mn 52

Figure 23. Global Biosimilars Market by Recombinant Glycosylated Biosimilars: Monoclonal Antibodies (mAb), 2019-2030, USD mn 53

Figure 24. Global Biosimilars Market by Recombinant Glycosylated Biosimilars: Erythropoietin (EPO), 2019-2030, USD mn 54

Figure 25. Global Biosimilars Market by Recombinant Glycosylated Biosimilars: Follicle Stimulating Hormone, 2019-2030, USD mn 55

Figure 26. Global Biosimilars Market by Product Type: Recombinant Peptides and Others, 2019-2030, USD mn 56

Figure 27. Global Biosimilars Market by Recombinant Peptides and Others: Tumor Necrosis Factor (TNF)-Inhibitor, 2019-2030, USD mn 57

Figure 28. Global Biosimilars Market by Recombinant Peptides and Others: Parathyroid Hormone, 2019-2030, USD mn 58

Figure 29. Global Biosimilars Market by Recombinant Peptides and Others: Enzymes, Immunomodulators, GnRH Analogs and Others, 2019-2030, USD mn 59

Figure 30. Breakdown of Global Biosimilars Market by Indication, 2019-2030, % of Sales Revenue 61

Figure 31. Global Addressable Market Cap in 2021-2030 by Indication, Value (USD mn) and Share (%) 61

Figure 32. Global Biosimilars Market by Indication: Cancer, 2019-2030, USD mn 62

Figure 33. Global Biosimilars Market by Indication: Autoimmune Disease, 2019-2030, USD mn 63

Figure 34. Global Biosimilars Market by Indication: Blood Disorder, 2019-2030, USD mn 64

Figure 35. Global Biosimilars Market by Indication: Diabetes, 2019-2030, USD mn 65

Figure 36. Global Biosimilars Market by Indication: Growth Hormone Deficiency, 2019-2030, USD mn 66

Figure 37. Global Biosimilars Market by Indication: Infectious Diseases, 2019-2030, USD mn 67

Figure 38. Global Biosimilars Market by Indication: Other Indications, 2019-2030, USD mn 68

Figure 39. Breakdown of Global Biosimilars Market by Manufacturing, 2019-2030, % of Sales Revenue 70

Figure 40. Global Addressable Market Cap in 2021-2030 by Manufacturing, Value (USD mn) and Share (%) 70

Figure 41. Global Biosimilars Market by Manufacturing: Contract Manufacturing, 2019-2030, USD mn 71

Figure 42. Global Biosimilars Market by Manufacturing: Inhouse Manufacturing, 2019-2030, USD mn 72

Figure 43. Breakdown of Global Biosimilars Market by End User, 2019-2030, % of Revenue 74

Figure 44. Global Addressable Market Cap in 2021-2030 by End User, Value (USD mn) and Share (%) 74

Figure 45. Global Biosimilars Market by End User: Hospitals and Clinics, 2019-2030, USD mn 75

Figure 46. Global Biosimilars Market by End User: Research Institutes, 2019-2030, USD mn 76

Figure 47. Global Biosimilars Market by End User: Other End Users, 2019-2030, USD mn 77

Figure 48. Global Market Snapshot by Region 78

Figure 49. Geographic Spread of Worldwide Biosimilars Market, 2019-2030, % of Sales Revenue 79

Figure 50. Global Addressable Market Cap in 2021-2030 by Region, Value (USD mn) and Share (%) 80

Figure 51. North American Biosimilars Market, 2019-2030, USD mn 83

Figure 52. Breakdown of North America Biosimilars Market by Country, 2019 and 2030, % of Revenue 84

Figure 53. Contribution to North America 2021-2030 Cumulative Market by Country, Value (USD mn) and Share (%) 85

Figure 54. U.S. Biosimilars Market, 2019-2030, USD mn 87

Figure 55. Biosimilar Approvals and Launches in U.S., 2015-2020 87

Figure 56. Canada Biosimilars Market, 2019-2030, USD mn 96

Figure 57. Biosimilars Market in Mexico, 2019-2030, USD mn 98

Figure 58. European Biosimilars Market, 2019-2030, USD mn 101

Figure 59. Breakdown of European Biosimilars Market by Country, 2019 and 2030, % of Revenue 102

Figure 60. Contribution to Europe 2021-2030 Cumulative Market by Country, Value (USD mn) and Share (%) 103

Figure 61. Biosimilars Market in Germany, 2019-2030, USD mn 106

Figure 62. Biosimilars Market in U.K., 2019-2030, USD mn 108

Figure 63. Biosimilars Market in France, 2019-2030, USD mn 110

Figure 64. Biosimilars Market in Spain, 2019-2030, USD mn 112

Figure 65. Biosimilars Market in Italy, 2019-2030, USD mn 114

Figure 66. Biosimilars Market in Russia, 2019-2030, USD mn 116

Figure 67. Biosimilars Market in Rest of Europe, 2019-2030, USD mn 118

Figure 68. Asia-Pacific Biosimilars Market, 2019-2030, USD mn 121

Figure 69. Breakdown of APAC Biosimilars Market by Country, 2019 and 2030, % of Revenue 121

Figure 70. Contribution to APAC 2021-2030 Cumulative Market by Country, Value (USD mn) and Share (%) 123

Figure 71. Biosimilars Market in Japan, 2019-2030, USD mn 125

Figure 72. Biosimilars Market in China, 2019-2030, USD mn 127

Figure 73. Biosimilars Market in Australia, 2019-2030, USD mn 129

Figure 74. Biosimilars Market in India, 2019-2030, USD mn 131

Figure 75. Biosimilars Market in South Korea, 2019-2030, USD mn 133

Figure 76. Biosimilars Market in Rest of APAC, 2019-2030, USD mn 135

Figure 77. South America Biosimilars Market, 2019-2030, USD mn 138

Figure 78. Breakdown of South America Biosimilars Market by Country, 2019 and 2030, % of Revenue 138

Figure 79. Contribution to South America 2021-2030 Cumulative Market by Country, Value (USD mn) and Share (%) 139

Figure 80. Biosimilars Market in Argentina, 2019-2030, USD mn 140

Figure 81. Biosimilars Market in Brazil, 2019-2030, USD mn 142

Figure 82. Biosimilars Market in Chile, 2019-2030, USD mn 144

Figure 83. Biosimilars Market in Rest of South America, 2019-2030, USD mn 146

Figure 84. Biosimilars Market in Middle East and Africa (MEA), 2019-2030, USD mn 148

Figure 85. Breakdown of MEA Biosimilars Market by Country, 2019 and 2030, % of Revenue 148

Figure 86. Contribution to MEA 2021-2030 Cumulative Market by Country, Value (USD mn) and Share (%) 149

Figure 87. Biosimilars Market in Turkey, 2019-2030, USD mn 150

Figure 88. Biosimilars Market in Iran, 2019-2030, USD mn 152

Figure 89. Biosimilars Market in South Africa, 2019-2030, USD mn 154

Figure 90. Growth Stage of Global Biosimilars Industry over the Forecast Period 157


List Of Table

List of Tables:

 

Table 1. Snapshot of Global Biosimilars Market in Balanced Perspective, 2019-2030 19

Table 2. Growth Rate of World GDP, 2020-2022 24

Table 3. World Health Spending by Region, USD bn, 2013-2020 32

Table 4. Main Product Trends and Market Opportunities in Global Biosimilars Market 36

Table 5. Global Biosimilars Market by Product Type, 2019-2030, USD mn 44

Table 6. Global Biosimilars Market: Recombinant Non-glycosylated Biosimilars by Product, 2019-2030, USD mn 47

Table 7. Global Biosimilars Market: Recombinant Glycosylated Biosimilars by Product, 2019-2030, USD mn 52

Table 8. Global Biosimilars Market: Recombinant Peptides and Others by Product, 2019-2030, USD mn 56

Table 9. Global Biosimilars Market by Indication, 2019-2030, USD mn 60

Table 10. Global Biosimilars Market by Manufacturing, 2019-2030, USD mn 69

Table 11. Global Biosimilars Market by End User, 2019-2030, USD mn 73

Table 12. Global Biosimilars Market by Region, 2019-2030, USD mn 79

Table 13. Leading National Biosimilars Market, 2019 and 2030F, USD mn 81

Table 14. North America Biosimilars Market by Country, 2019-2030, USD mn 84

Table 15. U.S. Biosimilars Market by Product Type, 2019-2030, USD mn 89

Table 16. U.S. Biosimilars Market by Indication, 2019-2030, USD mn 89

Table 17. U.S. Biosimilars Market by End User, 2019-2030, USD mn 89

Table 18. FDA Approved Biosimilars in U.S., 2015-2020 90

Table 19. U.S. Select Pending Biosimilar BLAs as of December 2020 94

Table 20. U.S. Biosimilar Market Share (market share data through July 2020) 95

Table 21. Canada Biosimilars Market by Product Type, 2019-2030, USD mn 97

Table 22. Canada Biosimilars Market by Indication, 2019-2030, USD mn 97

Table 23. Canada Biosimilars Market by End User, 2019-2030, USD mn 97

Table 24. Mexico Biosimilars Market by Product Type, 2019-2030, USD mn 99

Table 25. Mexico Biosimilars Market by Indication, 2019-2030, USD mn 99

Table 26. Mexico Biosimilars Market by End User, 2019-2030, USD mn 99

Table 27. Europe Biosimilars Market by Country, 2019-2030, USD mn 103

Table 28. Approved Biosimilars in Europe 104

Table 29. Germany Biosimilars Market by Product Type, 2019-2030, USD mn 107

Table 30. Germany Biosimilars Market by Indication, 2019-2030, USD mn 107

Table 31. Germany Biosimilars Market by End User, 2019-2030, USD mn 107

Table 32. U.K. Biosimilars Market by Product Type, 2019-2030, USD mn 109

Table 33. U.K. Biosimilars Market by Indication, 2019-2030, USD mn 109

Table 34. U.K. Biosimilars Market by End User, 2019-2030, USD mn 109

Table 35. France Biosimilars Market by Product Type, 2019-2030, USD mn 111

Table 36. France Biosimilars Market by Indication, 2019-2030, USD mn 111

Table 37. France Biosimilars Market by End User, 2019-2030, USD mn 111

Table 38. Spain Biosimilars Market by Product Type, 2019-2030, USD mn 113

Table 39. Spain Biosimilars Market by Indication, 2019-2030, USD mn 113

Table 40. Spain Biosimilars Market by End User, 2019-2030, USD mn 113

Table 41. Italy Biosimilars Market by Product Type, 2019-2030, USD mn 115

Table 42. Italy Biosimilars Market by Indication, 2019-2030, USD mn 115

Table 43. Italy Biosimilars Market by End User, 2019-2030, USD mn 115

Table 44. Russia Biosimilars Market by Product Type, 2019-2030, USD mn 117

Table 45. Russia Biosimilars Market by Indication, 2019-2030, USD mn 117

Table 46. Russia Biosimilars Market by End User, 2019-2030, USD mn 117

Table 47. Biosimilars Market in Rest of Europe by Country, 2019-2030, USD mn 119

Table 48. APAC Biosimilars Market by Country, 2019-2030, USD mn 122

Table 49. Japan Biosimilars Market by Product Type, 2019-2030, USD mn 126

Table 50. Japan Biosimilars Market by Indication, 2019-2030, USD mn 126

Table 51. Japan Biosimilars Market by End User, 2019-2030, USD mn 126

Table 52. China Biosimilars Market by Product Type, 2019-2030, USD mn 128

Table 53. China Biosimilars Market by Indication, 2019-2030, USD mn 128

Table 54. China Biosimilars Market by End User, 2019-2030, USD mn 128

Table 55. Australia Biosimilars Market by Product Type, 2019-2030, USD mn 130

Table 56. Australia Biosimilars Market by Indication, 2019-2030, USD mn 130

Table 57. Australia Biosimilars Market by End User, 2019-2030, USD mn 130

Table 58. India Biosimilars Market by Product Type, 2019-2030, USD mn 132

Table 59. India Biosimilars Market by Indication, 2019-2030, USD mn 132

Table 60. India Biosimilars Market by End User, 2019-2030, USD mn 132

Table 61. South Korea Biosimilars Market by Product Type, 2019-2030, USD mn 134

Table 62. South Korea Biosimilars Market by Indication, 2019-2030, USD mn 134

Table 63. South Korea Biosimilars Market by End User, 2019-2030, USD mn 134

Table 64. Biosimilars Market in Rest of APAC by Country/Region, 2019-2030, USD mn 136

Table 65. South America Biosimilars Market by Country, 2019-2030, USD mn 139

Table 66. Argentina Biosimilars Market by Product Type, 2019-2030, USD mn 141

Table 67. Argentina Biosimilars Market by Indication, 2019-2030, USD mn 141

Table 68. Argentina Biosimilars Market by End User, 2019-2030, USD mn 141

Table 69. Brazil Biosimilars Market by Product Type, 2019-2030, USD mn 143

Table 70. Brazil Biosimilars Market by Indication, 2019-2030, USD mn 143

Table 71. Brazil Biosimilars Market by End User, 2019-2030, USD mn 143

Table 72. Chile Biosimilars Market by Product Type, 2019-2030, USD mn 145

Table 73. Chile Biosimilars Market by Indication, 2019-2030, USD mn 145

Table 74. Chile Biosimilars Market by End User, 2019-2030, USD mn 145

Table 75. MEA Biosimilars Market by Country, 2019-2030, USD mn 149

Table 76. Turkey Biosimilars Market by Product Type, 2019-2030, USD mn 151

Table 77. Turkey Biosimilars Market by Indication, 2019-2030, USD mn 151

Table 78. Turkey Biosimilars Market by End User, 2019-2030, USD mn 151

Table 79. Iran Biosimilars Market by Product Type, 2019-2030, USD mn 153

Table 80. Iran Biosimilars Market by Indication, 2019-2030, USD mn 153

Table 81. Iran Biosimilars Market by End User, 2019-2030, USD mn 153

Table 82. South Africa Biosimilars Market by Product Type, 2019-2030, USD mn 155

Table 83. South Africa Biosimilars Market by Indication, 2019-2030, USD mn 155

Table 84. South Africa Biosimilars Market by End User, 2019-2030, USD mn 155

Table 85. Breakdown of World Market by Key Vendor, 2020, % 159

Table 86. AMEGA Biotech S.A.: Company Snapshot 162

Table 87. AMEGA Biotech S.A.: Business Segmentation 162

Table 88. AMEGA Biotech S.A.: Product Portfolio 163

Table 89. AMEGA Biotech S.A.: Revenue, 2018-2020, USD mn 163

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Key Players (this may not be a complete list and extra companies can be added upon request):

AMEGA Biotech S.A.

Apotex Inc.

Biocon Ltd

Biogen Inc.

Boehringer Ingelheim

Celltrion, Inc.

Dr. Reddy's Laboratories Ltd.

Eli Lilly and Company

Intas Pharmaceuticals Ltd.

LG Chem, Ltd.

Merck and Co. Inc.

Mylan N.V.

Pfizer Inc.

Samsung Biologics Co., Ltd.

Sandoz International GmbH

STADA Arzneimittel AG

Teva Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Company Profile

Company Profile Title

Global biosimilars market will reach USD 113.25 billion by 2030, growing by 25.7% annually over 2020-2030 driven by the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent expirations of many blockbuster drugs, and better healthcare provisions.

Highlighted with 89 tables and 90 figures, this 180-page report Global Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Region: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire global biosimilars market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).

In-depth qualitative analyses include identification and investigation of the following aspects:

Market Structure

Growth Drivers

Restraints and Challenges

Emerging Product Trends & Market Opportunities

Porter's Fiver Forces

The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global biosimilars market in every aspect of the classification from perspectives of Product Type, Indication, Manufacturing, End User, and Region.

 

Based on Product Type, the global market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Recombinant Non-glycosylated Biosimilars

o Insulin

o Recombinant Human Growth Hormone (rHGH)

o Granulocyte Colony Stimulating Factor

o Interferon

Recombinant Glycosylated Biosimilars

o Monoclonal Antibodies (mAb)

o Erythropoietin (EPO)

o Follicle Stimulating Hormone

Recombinant Peptides and Others

o Tumor Necrosis Factor (TNF)-Inhibitor

o Parathyroid Hormone

o Enzymes, Immunomodulators, GnRH Analogs and Others

 

Based on Indication, the global market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Cancer

Autoimmune Disease

Blood Disorder

Diabetes

Growth Hormone Deficiency

Infectious Diseases

Other Indications

 

Based on Manufacturing, the global market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Contract Manufacturing

Inhouse Manufacturing

 

Based on End User, the global market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Hospitals and Clinics

Research Institutes

Other End Users

 

Geographically, the following regions together with the listed national/local markets are fully investigated:

North America (U.S., Canada, and Mexico)

Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)

APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)

South America (Brazil, Chile, Argentina, Rest of South America)

MEA (Turkey, Iran, South Africa)

For each aforementioned region and country, detailed analysis and data for annual revenue (USD mn) are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Product Type, Indication, and End User over the forecast years are also included.

 

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Key Players (this may not be a complete list and extra companies can be added upon request):

AMEGA Biotech S.A.

Apotex Inc.

Biocon Ltd

Biogen Inc.

Boehringer Ingelheim

Celltrion, Inc.

Dr. Reddy's Laboratories Ltd.

Eli Lilly and Company

Intas Pharmaceuticals Ltd.

LG Chem, Ltd.

Merck and Co. Inc.

Mylan N.V.

Pfizer Inc.

Samsung Biologics Co., Ltd.

Sandoz International GmbH

STADA Arzneimittel AG

Teva Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

READ MORE

Scope

1 Introduction 9

1.1 Industry Definition and Research Scope 9

1.1.1 Industry Definition 9

1.1.2 Research Scope 10

1.2 Research Methodology 13

1.2.1 Overview of Market Research Methodology 13

1.2.2 Market Assumption 14

1.2.3 Secondary Data 14

1.2.4 Primary Data 14

1.2.5 Data Filtration and Model Design 15

1.2.6 Market Size/Share Estimation 16

1.2.7 Research Limitations 17

1.3 Executive Summary 18

2 Market Overview and Dynamics 20

2.1 Market Size and Forecast 20

2.1.1 Impact of COVID-19 on World Economy 23

2.1.2 Impact of COVID-19 on the Market 26

2.2 Major Growth Drivers 28

2.3 Market Restraints and Challenges 33

2.4 Emerging Opportunities and Market Trends 36

2.5 Porter's Fiver Forces Analysis 40

3 Segmentation of Global Market by Product Type 44

3.1 Market Overview by Product Type 44

3.2 Recombinant Non-glycosylated Biosimilars 46

3.2.1 Insulin 48

3.2.2 Recombinant Human Growth Hormone (rHGH) 49

3.2.3 Granulocyte Colony Stimulating Factor 50

3.2.4 Interferon 51

3.3 Recombinant Glycosylated Biosimilars 52

3.3.1 Monoclonal Antibodies (mAb) 53

3.3.2 Erythropoietin (EPO) 54

3.3.3 Follicle Stimulating Hormone 55

3.4 Recombinant Peptides and Others 56

3.4.1 Tumor Necrosis Factor (TNF)-Inhibitor 57

3.4.2 Parathyroid Hormone 58

3.4.3 Enzymes, Immunomodulators, GnRH Analogs and Others 59

4 Segmentation of Global Market by Indication 60

4.1 Market Overview by Indication 60

4.2 Cancer 62

4.3 Autoimmune Disease 63

4.4 Blood Disorder 64

4.5 Diabetes 65

4.6 Growth Hormone Deficiency 66

4.7 Infectious Diseases 67

4.8 Other Indications 68

5 Segmentation of Global Market by Manufacturing 69

5.1 Market Overview by Manufacturing 69

5.2 Contract Manufacturing 71

5.3 Inhouse Manufacturing 72

6 Segmentation of Global Market by End User 73

6.1 Market Overview by End User 73

6.2 Hospitals and Clinics 75

6.3 Research Institutes 76

6.4 Other End Users 77

7 Segmentation of Global Market by Region 78

7.1 Geographic Market Overview 2019-2030 78

7.2 North America Market 2019-2030 by Country 82

7.2.1 Overview of North America Market 82

7.2.2 U.S. 86

7.2.3 Canada 96

7.2.4 Mexico 98

7.3 European Market 2019-2030 by Country 100

7.3.1 Overview of European Market 100

7.3.2 Germany 106

7.3.3 U.K. 108

7.3.4 France 110

7.3.5 Spain 112

7.3.6 Italy 114

7.3.7 Russia 116

7.3.8 Rest of European Market 118

7.4 Asia-Pacific Market 2019-2030 by Country 120

7.4.1 Overview of Asia-Pacific Market 120

7.4.2 Japan 124

7.4.3 China 127

7.4.4 Australia 129

7.4.5 India 131

7.4.6 South Korea 133

7.4.7 Rest of APAC Region 135

7.5 South America Market 2019-2030 by Country 137

7.5.1 Argentina 140

7.5.2 Brazil 142

7.5.3 Chile 144

7.5.4 Rest of South America Market 146

7.6 MEA Market 2019-2030 by Country 147

7.6.1 Turkey 150

7.6.2 Iran 152

7.6.3 South Africa 154

7.6.4 Other National Markets 156

8 Competitive Landscape 157

8.1 Overview of Key Vendors 157

8.2 New Product Launch, Partnership, Investment, and M&A 161

8.3 Company Profiles 162

AMEGA Biotech S.A. 162

Apotex Inc. 164

Biocon Ltd 165

Biogen Inc. 166

Boehringer Ingelheim 167

Celltrion, Inc. 168

Dr. Reddy's Laboratories Ltd. 169

Eli Lilly and Company 170

Intas Pharmaceuticals Ltd. 171

LG Chem, Ltd. 172

Merck and Co. Inc. 173

Mylan N.V. 174

Pfizer Inc. 175

Samsung Biologics Co., Ltd. 176

Sandoz International GmbH 177

STADA Arzneimittel AG 178

Teva Pharmaceutical Industries Ltd. 179

RELATED REPORTS 180


List Of Figure

List of Figures:

 

Figure 1. Research Method Flow Chart 13

Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 16

Figure 3. Global Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 18

Figure 4. Global Biosimilars Market, 2019-2030, USD mn 20

Figure 5. EMA and FDA Biosimilar Approvals, 2015 - 2019 21

Figure 6. EMA-approved Biosimilars Distribution by Reference Product and Therapeutic Area 21

Figure 7. FDA-approved Biosimilars Distribution by Reference Product and Therapeutic Area 22

Figure 8. Impact of COVID-19 on Business 26

Figure 9. Primary Drivers and Impact Factors of Global Biosimilars Market 28

Figure 10. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 31

Figure 11. World Population 65 and Over, % of Total Population, 1950-2060 31

Figure 12. Primary Restraints and Impact Factors of Global Biosimilars Market 33

Figure 13. Investment Opportunity Analysis 37

Figure 14. Porter's Fiver Forces Analysis of Global Biosimilars Market 40

Figure 15. Breakdown of Global Biosimilars Market by Product Type, 2019-2030, % of Revenue 45

Figure 16. Global Addressable Market Cap in 2021-2030 by Product Type, Value (USD mn) and Share (%) 45

Figure 17. Global Biosimilars Market by Product Type: Recombinant Non-glycosylated Biosimilars, 2019-2030, USD mn 46

Figure 18. Global Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Insulin, 2019-2030, USD mn 48

Figure 19. Global Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Recombinant Human Growth Hormone (rHGH), 2019-2030, USD mn 49

Figure 20. Global Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Granulocyte Colony Stimulating Factor, 2019-2030, USD mn 50

Figure 21. Global Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Interferon, 2019-2030, USD mn 51

Figure 22. Global Biosimilars Market by Product Type: Recombinant Glycosylated Biosimilars, 2019-2030, USD mn 52

Figure 23. Global Biosimilars Market by Recombinant Glycosylated Biosimilars: Monoclonal Antibodies (mAb), 2019-2030, USD mn 53

Figure 24. Global Biosimilars Market by Recombinant Glycosylated Biosimilars: Erythropoietin (EPO), 2019-2030, USD mn 54

Figure 25. Global Biosimilars Market by Recombinant Glycosylated Biosimilars: Follicle Stimulating Hormone, 2019-2030, USD mn 55

Figure 26. Global Biosimilars Market by Product Type: Recombinant Peptides and Others, 2019-2030, USD mn 56

Figure 27. Global Biosimilars Market by Recombinant Peptides and Others: Tumor Necrosis Factor (TNF)-Inhibitor, 2019-2030, USD mn 57

Figure 28. Global Biosimilars Market by Recombinant Peptides and Others: Parathyroid Hormone, 2019-2030, USD mn 58

Figure 29. Global Biosimilars Market by Recombinant Peptides and Others: Enzymes, Immunomodulators, GnRH Analogs and Others, 2019-2030, USD mn 59

Figure 30. Breakdown of Global Biosimilars Market by Indication, 2019-2030, % of Sales Revenue 61

Figure 31. Global Addressable Market Cap in 2021-2030 by Indication, Value (USD mn) and Share (%) 61

Figure 32. Global Biosimilars Market by Indication: Cancer, 2019-2030, USD mn 62

Figure 33. Global Biosimilars Market by Indication: Autoimmune Disease, 2019-2030, USD mn 63

Figure 34. Global Biosimilars Market by Indication: Blood Disorder, 2019-2030, USD mn 64

Figure 35. Global Biosimilars Market by Indication: Diabetes, 2019-2030, USD mn 65

Figure 36. Global Biosimilars Market by Indication: Growth Hormone Deficiency, 2019-2030, USD mn 66

Figure 37. Global Biosimilars Market by Indication: Infectious Diseases, 2019-2030, USD mn 67

Figure 38. Global Biosimilars Market by Indication: Other Indications, 2019-2030, USD mn 68

Figure 39. Breakdown of Global Biosimilars Market by Manufacturing, 2019-2030, % of Sales Revenue 70

Figure 40. Global Addressable Market Cap in 2021-2030 by Manufacturing, Value (USD mn) and Share (%) 70

Figure 41. Global Biosimilars Market by Manufacturing: Contract Manufacturing, 2019-2030, USD mn 71

Figure 42. Global Biosimilars Market by Manufacturing: Inhouse Manufacturing, 2019-2030, USD mn 72

Figure 43. Breakdown of Global Biosimilars Market by End User, 2019-2030, % of Revenue 74

Figure 44. Global Addressable Market Cap in 2021-2030 by End User, Value (USD mn) and Share (%) 74

Figure 45. Global Biosimilars Market by End User: Hospitals and Clinics, 2019-2030, USD mn 75

Figure 46. Global Biosimilars Market by End User: Research Institutes, 2019-2030, USD mn 76

Figure 47. Global Biosimilars Market by End User: Other End Users, 2019-2030, USD mn 77

Figure 48. Global Market Snapshot by Region 78

Figure 49. Geographic Spread of Worldwide Biosimilars Market, 2019-2030, % of Sales Revenue 79

Figure 50. Global Addressable Market Cap in 2021-2030 by Region, Value (USD mn) and Share (%) 80

Figure 51. North American Biosimilars Market, 2019-2030, USD mn 83

Figure 52. Breakdown of North America Biosimilars Market by Country, 2019 and 2030, % of Revenue 84

Figure 53. Contribution to North America 2021-2030 Cumulative Market by Country, Value (USD mn) and Share (%) 85

Figure 54. U.S. Biosimilars Market, 2019-2030, USD mn 87

Figure 55. Biosimilar Approvals and Launches in U.S., 2015-2020 87

Figure 56. Canada Biosimilars Market, 2019-2030, USD mn 96

Figure 57. Biosimilars Market in Mexico, 2019-2030, USD mn 98

Figure 58. European Biosimilars Market, 2019-2030, USD mn 101

Figure 59. Breakdown of European Biosimilars Market by Country, 2019 and 2030, % of Revenue 102

Figure 60. Contribution to Europe 2021-2030 Cumulative Market by Country, Value (USD mn) and Share (%) 103

Figure 61. Biosimilars Market in Germany, 2019-2030, USD mn 106

Figure 62. Biosimilars Market in U.K., 2019-2030, USD mn 108

Figure 63. Biosimilars Market in France, 2019-2030, USD mn 110

Figure 64. Biosimilars Market in Spain, 2019-2030, USD mn 112

Figure 65. Biosimilars Market in Italy, 2019-2030, USD mn 114

Figure 66. Biosimilars Market in Russia, 2019-2030, USD mn 116

Figure 67. Biosimilars Market in Rest of Europe, 2019-2030, USD mn 118

Figure 68. Asia-Pacific Biosimilars Market, 2019-2030, USD mn 121

Figure 69. Breakdown of APAC Biosimilars Market by Country, 2019 and 2030, % of Revenue 121

Figure 70. Contribution to APAC 2021-2030 Cumulative Market by Country, Value (USD mn) and Share (%) 123

Figure 71. Biosimilars Market in Japan, 2019-2030, USD mn 125

Figure 72. Biosimilars Market in China, 2019-2030, USD mn 127

Figure 73. Biosimilars Market in Australia, 2019-2030, USD mn 129

Figure 74. Biosimilars Market in India, 2019-2030, USD mn 131

Figure 75. Biosimilars Market in South Korea, 2019-2030, USD mn 133

Figure 76. Biosimilars Market in Rest of APAC, 2019-2030, USD mn 135

Figure 77. South America Biosimilars Market, 2019-2030, USD mn 138

Figure 78. Breakdown of South America Biosimilars Market by Country, 2019 and 2030, % of Revenue 138

Figure 79. Contribution to South America 2021-2030 Cumulative Market by Country, Value (USD mn) and Share (%) 139

Figure 80. Biosimilars Market in Argentina, 2019-2030, USD mn 140

Figure 81. Biosimilars Market in Brazil, 2019-2030, USD mn 142

Figure 82. Biosimilars Market in Chile, 2019-2030, USD mn 144

Figure 83. Biosimilars Market in Rest of South America, 2019-2030, USD mn 146

Figure 84. Biosimilars Market in Middle East and Africa (MEA), 2019-2030, USD mn 148

Figure 85. Breakdown of MEA Biosimilars Market by Country, 2019 and 2030, % of Revenue 148

Figure 86. Contribution to MEA 2021-2030 Cumulative Market by Country, Value (USD mn) and Share (%) 149

Figure 87. Biosimilars Market in Turkey, 2019-2030, USD mn 150

Figure 88. Biosimilars Market in Iran, 2019-2030, USD mn 152

Figure 89. Biosimilars Market in South Africa, 2019-2030, USD mn 154

Figure 90. Growth Stage of Global Biosimilars Industry over the Forecast Period 157


List Of Table

List of Tables:

 

Table 1. Snapshot of Global Biosimilars Market in Balanced Perspective, 2019-2030 19

Table 2. Growth Rate of World GDP, 2020-2022 24

Table 3. World Health Spending by Region, USD bn, 2013-2020 32

Table 4. Main Product Trends and Market Opportunities in Global Biosimilars Market 36

Table 5. Global Biosimilars Market by Product Type, 2019-2030, USD mn 44

Table 6. Global Biosimilars Market: Recombinant Non-glycosylated Biosimilars by Product, 2019-2030, USD mn 47

Table 7. Global Biosimilars Market: Recombinant Glycosylated Biosimilars by Product, 2019-2030, USD mn 52

Table 8. Global Biosimilars Market: Recombinant Peptides and Others by Product, 2019-2030, USD mn 56

Table 9. Global Biosimilars Market by Indication, 2019-2030, USD mn 60

Table 10. Global Biosimilars Market by Manufacturing, 2019-2030, USD mn 69

Table 11. Global Biosimilars Market by End User, 2019-2030, USD mn 73

Table 12. Global Biosimilars Market by Region, 2019-2030, USD mn 79

Table 13. Leading National Biosimilars Market, 2019 and 2030F, USD mn 81

Table 14. North America Biosimilars Market by Country, 2019-2030, USD mn 84

Table 15. U.S. Biosimilars Market by Product Type, 2019-2030, USD mn 89

Table 16. U.S. Biosimilars Market by Indication, 2019-2030, USD mn 89

Table 17. U.S. Biosimilars Market by End User, 2019-2030, USD mn 89

Table 18. FDA Approved Biosimilars in U.S., 2015-2020 90

Table 19. U.S. Select Pending Biosimilar BLAs as of December 2020 94

Table 20. U.S. Biosimilar Market Share (market share data through July 2020) 95

Table 21. Canada Biosimilars Market by Product Type, 2019-2030, USD mn 97

Table 22. Canada Biosimilars Market by Indication, 2019-2030, USD mn 97

Table 23. Canada Biosimilars Market by End User, 2019-2030, USD mn 97

Table 24. Mexico Biosimilars Market by Product Type, 2019-2030, USD mn 99

Table 25. Mexico Biosimilars Market by Indication, 2019-2030, USD mn 99

Table 26. Mexico Biosimilars Market by End User, 2019-2030, USD mn 99

Table 27. Europe Biosimilars Market by Country, 2019-2030, USD mn 103

Table 28. Approved Biosimilars in Europe 104

Table 29. Germany Biosimilars Market by Product Type, 2019-2030, USD mn 107

Table 30. Germany Biosimilars Market by Indication, 2019-2030, USD mn 107

Table 31. Germany Biosimilars Market by End User, 2019-2030, USD mn 107

Table 32. U.K. Biosimilars Market by Product Type, 2019-2030, USD mn 109

Table 33. U.K. Biosimilars Market by Indication, 2019-2030, USD mn 109

Table 34. U.K. Biosimilars Market by End User, 2019-2030, USD mn 109

Table 35. France Biosimilars Market by Product Type, 2019-2030, USD mn 111

Table 36. France Biosimilars Market by Indication, 2019-2030, USD mn 111

Table 37. France Biosimilars Market by End User, 2019-2030, USD mn 111

Table 38. Spain Biosimilars Market by Product Type, 2019-2030, USD mn 113

Table 39. Spain Biosimilars Market by Indication, 2019-2030, USD mn 113

Table 40. Spain Biosimilars Market by End User, 2019-2030, USD mn 113

Table 41. Italy Biosimilars Market by Product Type, 2019-2030, USD mn 115

Table 42. Italy Biosimilars Market by Indication, 2019-2030, USD mn 115

Table 43. Italy Biosimilars Market by End User, 2019-2030, USD mn 115

Table 44. Russia Biosimilars Market by Product Type, 2019-2030, USD mn 117

Table 45. Russia Biosimilars Market by Indication, 2019-2030, USD mn 117

Table 46. Russia Biosimilars Market by End User, 2019-2030, USD mn 117

Table 47. Biosimilars Market in Rest of Europe by Country, 2019-2030, USD mn 119

Table 48. APAC Biosimilars Market by Country, 2019-2030, USD mn 122

Table 49. Japan Biosimilars Market by Product Type, 2019-2030, USD mn 126

Table 50. Japan Biosimilars Market by Indication, 2019-2030, USD mn 126

Table 51. Japan Biosimilars Market by End User, 2019-2030, USD mn 126

Table 52. China Biosimilars Market by Product Type, 2019-2030, USD mn 128

Table 53. China Biosimilars Market by Indication, 2019-2030, USD mn 128

Table 54. China Biosimilars Market by End User, 2019-2030, USD mn 128

Table 55. Australia Biosimilars Market by Product Type, 2019-2030, USD mn 130

Table 56. Australia Biosimilars Market by Indication, 2019-2030, USD mn 130

Table 57. Australia Biosimilars Market by End User, 2019-2030, USD mn 130

Table 58. India Biosimilars Market by Product Type, 2019-2030, USD mn 132

Table 59. India Biosimilars Market by Indication, 2019-2030, USD mn 132

Table 60. India Biosimilars Market by End User, 2019-2030, USD mn 132

Table 61. South Korea Biosimilars Market by Product Type, 2019-2030, USD mn 134

Table 62. South Korea Biosimilars Market by Indication, 2019-2030, USD mn 134

Table 63. South Korea Biosimilars Market by End User, 2019-2030, USD mn 134

Table 64. Biosimilars Market in Rest of APAC by Country/Region, 2019-2030, USD mn 136

Table 65. South America Biosimilars Market by Country, 2019-2030, USD mn 139

Table 66. Argentina Biosimilars Market by Product Type, 2019-2030, USD mn 141

Table 67. Argentina Biosimilars Market by Indication, 2019-2030, USD mn 141

Table 68. Argentina Biosimilars Market by End User, 2019-2030, USD mn 141

Table 69. Brazil Biosimilars Market by Product Type, 2019-2030, USD mn 143

Table 70. Brazil Biosimilars Market by Indication, 2019-2030, USD mn 143

Table 71. Brazil Biosimilars Market by End User, 2019-2030, USD mn 143

Table 72. Chile Biosimilars Market by Product Type, 2019-2030, USD mn 145

Table 73. Chile Biosimilars Market by Indication, 2019-2030, USD mn 145

Table 74. Chile Biosimilars Market by End User, 2019-2030, USD mn 145

Table 75. MEA Biosimilars Market by Country, 2019-2030, USD mn 149

Table 76. Turkey Biosimilars Market by Product Type, 2019-2030, USD mn 151

Table 77. Turkey Biosimilars Market by Indication, 2019-2030, USD mn 151

Table 78. Turkey Biosimilars Market by End User, 2019-2030, USD mn 151

Table 79. Iran Biosimilars Market by Product Type, 2019-2030, USD mn 153

Table 80. Iran Biosimilars Market by Indication, 2019-2030, USD mn 153

Table 81. Iran Biosimilars Market by End User, 2019-2030, USD mn 153

Table 82. South Africa Biosimilars Market by Product Type, 2019-2030, USD mn 155

Table 83. South Africa Biosimilars Market by Indication, 2019-2030, USD mn 155

Table 84. South Africa Biosimilars Market by End User, 2019-2030, USD mn 155

Table 85. Breakdown of World Market by Key Vendor, 2020, % 159

Table 86. AMEGA Biotech S.A.: Company Snapshot 162

Table 87. AMEGA Biotech S.A.: Business Segmentation 162

Table 88. AMEGA Biotech S.A.: Product Portfolio 163

Table 89. AMEGA Biotech S.A.: Revenue, 2018-2020, USD mn 163

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Key Players (this may not be a complete list and extra companies can be added upon request):

AMEGA Biotech S.A.

Apotex Inc.

Biocon Ltd

Biogen Inc.

Boehringer Ingelheim

Celltrion, Inc.

Dr. Reddy's Laboratories Ltd.

Eli Lilly and Company

Intas Pharmaceuticals Ltd.

LG Chem, Ltd.

Merck and Co. Inc.

Mylan N.V.

Pfizer Inc.

Samsung Biologics Co., Ltd.

Sandoz International GmbH

STADA Arzneimittel AG

Teva Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)